Healthcare Services

NGS Oncology Market Trends and Insights: Global Forecast to 2030

February 27, 2026April 15, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the ngs oncology market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the NGS Oncology Market in 2030?

The ngs oncology market has seen significant and rapid expansion in its size over recent years. It is projected to expand from $19.33 billion in 2025 to $21.54 billion in 2026, at a compound annual growth rate (CAGR) of 11.4%. This historical growth can be ascribed to elements such as declining sequencing costs, rising global cancer prevalence, increased oncology research funding, early adoption of targeted therapies, and the proliferation of genomic research initiatives.

The ngs oncology market is projected to experience substantial growth over the next few years, with its size expected to reach $32.87 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.2%. This projected expansion during the forecast period is largely fueled by the increasing development of precision oncology programs, a rising need for individualized cancer treatments, the growing number of approvals for ngs-based diagnostic tools, continuous innovations in bioinformatics analytics, and the incorporation of ngs into standard clinical guidelines. Significant trends for this period encompass the broader adoption of comprehensive tumor profiling, the increasing use of liquid biopsy NGS, the enhanced clinical value of multi-gene panels, the embedding of NGS in routine oncology diagnostic processes, and the escalating demand for more rapid sequencing workflows.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24337&type=smp

What Drivers Are Influencing Production Trends In The NGS Oncology Market?

The escalating incidence of cancer is anticipated to fuel the expansion of the NGS oncology market in the future. Cancer is a condition characterized by the unrestrained proliferation of abnormal cells, which can invade other bodily regions and disrupt normal physiological functions. The rise in cancer cases is primarily driven by demographic shifts, including an aging population and overall population growth, alongside increased exposure to risk factors such as tobacco use, alcohol consumption, obesity, and air pollution. NGS oncology supports public health and patient management by enabling prompt detection, precise diagnosis, and personalized treatment through comprehensive genetic analysis of tumors. For instance, in January 2024, figures released by the American Cancer Society, a US-based non-profit organization, project that the United States will record 2,001,140 new cancer cases and 611,720 cancer deaths in 2024, an increase compared to 1,958,310 cases and 609,820 deaths in 2023. Consequently, the increasing prevalence of cancer is a key driver for the growth of the NGS oncology market.

Which Segments Are Gaining Traction In The NGS Oncology Market?

The ngs oncology market covered in this report is segmented –

1) By Sequencing Technology: Targeted Sequencing, Genomics, Transcriptomics, Epigenomics

2) By Offering: Platform, Kits, Services

3) By Workflow: Pre-Sequencing, Sequencing, Data Analysis

4) By Application: Genetic Screening, Hereditary Genetic Testing, Hematological Malignancies, Solid Tumors, Other Applications

5) By End User: Hospitals And Clinics, Clinical Research Organizations (CROs), Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users

Subsegments:

1) By Targeted Sequencing: Whole Exome Sequencing (WES), Amplicon-Based Sequencing, Hybridization-Based Sequencing

2) By Genomics: Whole Genome Sequencing (WGS), Structural Variant Detection, Copy Number Variation (CNV) Analysis

3) By Transcriptomics: RNA Sequencing, Single-Cell Transcriptomics, Non-Coding RNA Analysis

4) By Epigenomics: DNA Methylation Sequencing, Chromatin Immunoprecipitation Sequencing, Histone Modification Analysis

Which Trends Are Shaping Activity Within The NGS Oncology Market?

Major companies operating in the NGS oncology market are focusing on developing innovative solutions, such as liquid biopsy research assays, to enable non-invasive, real-time cancer detection and monitoring through the analysis of circulating tumor DNA. A liquid biopsy research assay is a diagnostic test that analyzes biological fluids, such as blood, to detect genetic mutations or other molecular markers associated with cancer, allowing for non-invasive cancer detection and monitoring. For instance, in August 2024, Illumina Inc., a US-based biotechnology company specializing in next-generation sequencing (NGS) technology, expanded its oncology portfolio for NovaSeq X Series users. The company now offers the newly validated high-throughput TruSight Oncology 500 (TSO 500 HT) and the updated TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) liquid biopsy research assay. These enhanced assays enable laboratories to broaden oncology research capabilities for both tissue and liquid biopsy samples, featuring improved sequencing efficiency, reduced run times, and the ability to process larger sample volumes on the NovaSeq X Series for the first time.

Who Are The Prominent Global Companies Shaping The NGS Oncology Market Landscape?

Major companies operating in the ngs oncology market are Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Eurofins Scientific SE, Illumina Inc., Qiagen N.V., Tecan Trading AG, Myriad Genetics, Takara Bio Inc., Beijing Genomics Institute (BGI), Caris Life Sciences, Foundation Medicine, Paradigm Diagnostics, Pacific Bioscience, Horizon Discovery Group plc , Creative-Biolabs, Xcelris Labs Ltd., Partek Inc., 4baseCare, SciGenom Labs Pvt. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/ngs-oncology-global-market-report

Which Region Is Projected To Lead The NGS Oncology Market During The Forecast Period?

North America was the largest region in the NGS oncology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ngs oncology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized NGS Oncology Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24337&type=smp

Browse Through More Reports Similar to the Global NGS Oncology Market 2026, By The Business Research Company

Oncology Companion Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-companion-diagnostics-global-market-report

Oncology Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Community Oncology Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795